Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Adverse Events of COVID-19 Vaccines"
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 31 December 2023 | Viewed by 486501
Special Issue Editor
Interests: meta-analysis; statistics; epidemiology
Special Issue Information
Although the vaccination is one of the effective protection against COVID-19 through the rapid development of COVID-19 pandemic, the unexpected adverse events (AEs) of vaccination has not been systematically reported.
Among the adolescent, rare severe adverse events associated with vaccines may not be identified in phase 3 trials because of the small sample size, restrictive inclusion criteria, limited duration of follow-up, and trial participants who may differ from the population ultimately receiving the vaccines .
Moreover, it has been widely reported that diabetes is undoubtedly associated with a poorer prognosis after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [2,3]. However, since most of the studies on side effects after COVID-19 vaccination are case reports, it is not accurately considered for type 2 diabetes.
In order to identify adverse reactions after COVID-19 vaccination, safety studies considering various covariates, such as race, age, and specific diseases, are needed. In particular, research to secure safety for adolescents and children, as well as high-quality clinical studies to understand the association of side effects with cardiovascular diseases, such as diabetes, is urgent from a health perspective.
- French, R.W., Jr.; et al. N. Engl. J. Med. 2021, 385, 239–250.
- Sathish, T.; et al. Diabetes Obes. Metab. 2021, 23, 870–874.
- Huang, I.; et al. Diabetes Metab. Syndr. 2020, 14, 395–403.
Prof. Dr. Sung Ryul Shim
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- COVID-19 vaccine
- real-world data
- adverse event
- systematic review